XFOR · X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals faced a stark revenue contraction in Q1 2026, with total revenue dropping 90.6% year-over-year to $2.7 million from $28.8 million. This decline stemmed primarily from the absence of non-recurring sublicense income and associated royalties from the Norgine Agreement that boosted the prior-year quarter, as noted in management discussion. Cost of revenue decreased accordingly, preserving a robust gross margin of 77.9% on the reduced $2.1 million gross profit—down 91.2% but indicative of the underlying strength in product sales economics.

Net product revenue, however, showed positive momentum, increasing over Q1 2025 levels primarily due to a higher number of patients prescribed the Company's drug product targeting WHIM syndrome, a rare combined primary immunodeficiency and congenital neutropenia (CN) disorder. This growth underscores commercial traction despite the topline headwind from lapsed license revenue.

Operating expenses reflected the impact of strategic restructuring actions implemented in 2025, which lowered compensation and related benefit costs. These efficiencies were partially offset by escalating clinical expenses as the Company advances its lead drug candidate through the 4WARD trial in patients with moderate and severe CN. The result was an operating loss widening 115.0% to -$20.3 million from -$9.4 million, with operating margin at -749.9%. Net income flipped to a -$20.2 million loss from a modest $282 thousand profit, driving diluted EPS to -$0.16 from $0.04—a 500% deterioration.

This quarter highlights X4's pivot toward sustainable product revenue and clinical milestones, tempered by one-time revenue normalization and investment demands. Restructuring benefits provide partial relief, but advancing the 4WARD trial remains the core driver of elevated losses, aligning with the long-term strategy to address CN in WHIM patients.